Want to see APLM full AI Analyst Report?
APLM Stock Chart & Stats
$18.21
$0.44(2.42%)
At close: 4:00 PM EDT
$18.21
$0.44(2.42%)
Day’s Range― - ―
52-Week Range$3.66 - $42.12
Previous CloseN/A
Volume30.00
Average Volume (3M)72.65K
Market Cap
$51.76M
Enterprise Value$12.77M
Total Cash (Recent Filing)$3.28M
Total Debt (Recent Filing)$643.00K
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.80
Shares Outstanding2,196,052
10 Day Avg. Volume95,090
30 Day Avg. Volume72,653
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-8.48
Price to Sales (P/S)3.18
P/FCF Ratio-2.61
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda4.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-122
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ExpansionThe sharp increase indicates improved partnering or commercial activity and could provide a larger base for future development funding. Its durability still depends on repeatable collaborations and product progress, but the scale-up is a meaningful change from 2024.
Modest Debt LoadDebt of roughly $0.6M is modest in absolute terms, limiting interest and repayment pressure relative to a heavily leveraged biotech. This gives the company some balance-sheet flexibility, although negative equity and cash burn materially constrain that advantage.
Reduced Cash BurnOperating and free-cash-flow burn improved from about $28.7M in 2024 to $10.4M in 2025. If sustained, lower annual cash consumption could extend funding runway and reduce financing needs, though cash generation remains negative.
Bears Say
Persistent Operating LossesLosses remain substantial despite higher revenue, with 2025 EBIT near negative $9.5M and net loss near negative $10.9M. Persistent unprofitability limits internally funded R&D and makes value creation dependent on clinical, partnering, or financing success.
Negative Free Cash FlowFree cash flow and operating cash flow were each about negative $10.4M in 2025. Continued cash consumption means Apollomics must fund trials and overhead externally, exposing shareholders to dilution or execution risk if financing becomes difficult.
Negative Shareholders’ EquityStockholders’ equity fell from positive $4.9M in 2024 to negative $3.2M in 2025. Negative equity reduces financial resilience and signals that accumulated losses have weakened the capital base, increasing dependence on new funding while the pipeline remains unapproved.
Apollomics News
APLM FAQ
What was Apollomics’s price range in the past 12 months?
Apollomics lowest stock price was $3.66 and its highest was $42.12 in the past 12 months.
What is Apollomics’s market cap?
Apollomics’s market cap is $51.76M.
When is Apollomics’s upcoming earnings report date?
Apollomics’s upcoming earnings report date is Sep 24, 2026 which is in 33 days.
How were Apollomics’s earnings last quarter?
Apollomics released its earnings results on Apr 27, 2026. The company reported $3.795 earnings per share for the quarter, beating the consensus estimate of N/A by $3.795.
Is Apollomics overvalued?
According to Wall Street analysts Apollomics’s price is currently Overvalued.
Does Apollomics pay dividends?
Apollomics does not currently pay dividends.
What is Apollomics’s EPS estimate?
Apollomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apollomics have?
Apollomics has 2,196,052 shares outstanding.
What happened to Apollomics’s price movement after its last earnings report?
Apollomics reported an EPS of $3.795 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.693%.
Which hedge fund is a major shareholder of Apollomics?
Currently, no hedge funds are holding shares in APLM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apollomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $8.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-48.74%
Trailing 12-Months
Company Description
Apollomics
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Technical Analysis
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Exicure
―
CytoMed Therapeutics Limited
―
Ownership Overview
74.79% Insiders
0.03% Mutual Funds
― Other Institutional Investors
25.18% Public Companies and
Individual Investors